Literature DB >> 7809631

Inhibition of ras-induced proliferation and cellular transformation by p16INK4.

M Serrano1, E Gómez-Lahoz, R A DePinho, D Beach, D Bar-Sagi.   

Abstract

The cyclin-dependent kinase 4 (CDK4) regulates progression through the G1 phase of the cell cycle. The activity of CDK4 is controlled by the opposing effects of the D-type cyclin, an activating subunit, and p16INK4, an inhibitory subunit. Ectopic expression of p16INK4 blocked entry into S phase of the cell cycle induced by oncogenic Ha-Ras, and this block was relieved by coexpression of a catalytically inactive CDK4 mutant. Expression of p16INK4 suppressed cellular transformation of primary rat embryo fibroblasts by oncogenic Ha-Ras and Myc, but not by Ha-Ras and E1a. Together, these observations provide direct evidence that p16INK4 can inhibit cell growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7809631     DOI: 10.1126/science.7809631

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  92 in total

1.  Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray.

Authors:  S Li; D T Ross; M E Kadin; P O Brown; M A Wasik
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

3.  Effect of 5-Aza-2'-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2.

Authors:  L H Liu; W H Xiao; W W Liu
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

4.  Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Authors:  Gottfried E Konecny; Boris Winterhoff; Teodora Kolarova; Jingwei Qi; Kanthinh Manivong; Judy Dering; Guorong Yang; Meenal Chalukya; He-Jing Wang; Lee Anderson; Kimberly R Kalli; Richard S Finn; Charles Ginther; Siân Jones; Victor E Velculescu; Darren Riehle; William A Cliby; Sophia Randolph; Maria Koehler; Lynn C Hartmann; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

Review 5.  Surprising dependency for retinoblastoma protein in ras-mediated tumorigenesis.

Authors:  James DeGregori
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

Review 6.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

Review 8.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

9.  Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo.

Authors:  A I Robles; M L Rodriguez-Puebla; A B Glick; C Trempus; L Hansen; P Sicinski; R W Tennant; R A Weinberg; S H Yuspa; C J Conti
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

10.  Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity.

Authors:  Hiroyuki Mitomi; Naoshi Fukui; Nobuho Tanaka; Hideki Kanazawa; Tsuyoshi Saito; Takashi Matsuoka; Takashi Yao
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.